The primary objective of the trial is to evaluate the tolerability and safety of anti-CHIKV hyperimmune immunoglobulins given intravenously to neonates exposed to a high risk of MTCT of CHIKV, i.e. born to a mother with definite or possible CHIKV infection at the time of delivery.